Design Therapeutics, Inc.
CARLSBAD, CA · Founded 2017 · CIK 0001807120 · Biotech · Public
Allele-specific gene modulator platform that silences mutant disease alleles in nucleotide repeat expansion disorders
designtx.com →- Grants
- $660K
- 2 awards
- Sector median: 1
- Raised
- $171M
- 2 Form D · Feb 2021
- 68 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 0 granted · 40 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Pre-clinical development of synthetic transcription elongation factors for the treatment of Friedreich's ataxia | $435,336 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Development of a genomic targeting drug delivery platform | $225,000 | |
| Private capital raised | Form D · SEC | $45,500,246 | |
| Private capital raised | Form D · SEC | $125,000,063 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1728 | PYROJAS INC | — | — |
| 1729 | Chicago Biosolutions, Inc. | — | — |
| 1730 | DEMERX, INC. | — | $290K |
| 1731 | Design Therapeutics, Inc. | — | $171M |
| 1732 | Halia Therapeutics, Inc. | — | $27M |
| 1733 | Iterum Therapeutics plc | — | $127M |
| 1734 | Jnana Therapeutics | — | $110M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Aseem Ansari, Ph.D.Director
- Simeon George, M.D.Director
- Sean Jeffries, Ph.D.Executive Officer
- Rodney Lappe, Ph.D.Director
- John SchmidDirector
- Pratik Shah, Ph.D.Director · Executive Officer
- Joao Siffert, M.D.Director · Executive Officer
- Arsani William, M.D.Director
- Stella Xu, Ph.D.Director
Patents
- Methods And Compositions For Treatment Of Ophthalmic Diseaseapplication
- Methods And Compounds For Modulating Inherited Genetic Diseasesapplication
- Compounds And Methods For Treating Friedreich's Ataxiaapplication
- Methods And Compounds For The Treatment Of Genetic Diseaseapplication
- Methods And Compounds For The Treatment Of Genetic Diseaseapplication
- Methods And Compounds For The Treatment Of Genetic Diseaseapplication
- Methods And Compounds For The Treatment Of Genetic Diseaseapplication
- Compounds And Methods For Treating Friedreich's Ataxiaapplication
- Process For Polyamide Synthesisapplication
- Methods And Compounds For The Treatment Of Genetic Diseaseapplication
- Methods And Compounds For Modulating Myotonic Dystropy 1application
- Methods And Compounds For Treating Friedreich's Ataxiaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.